BBIO Valuation

BridgeBio Pharma Inc

Add to Watchlist

Advanced Chart

61.980

-0.66(-1.054%)1D

BBIO Relative Valuation

BBIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BBIO is overvalued; if below, it's undervalued.

Historical Valuation

BridgeBio Pharma Inc (BBIO) is now in the Fair zone, suggesting that its current forward PS ratio of 62.64 is considered Fairly compared with the five-year average of -9.22. The fair price of BridgeBio Pharma Inc (BBIO) is between 18.88 to 135.28 according to relative valuation methord.

Relative Value

Fair Zone

18.88-135.28

Current Price：61.01

Fair

-27.11

Trailing

Forward

-57.24

EV/EBITDA

BridgeBio Pharma Inc. (BBIO) has a current EV/EBITDA of -57.24. The 5-year average EV/EBITDA is -13.65. The thresholds are as follows: Strongly Undervalued below -29.16, Undervalued between -29.16 and -21.40, Fairly Valued between -5.89 and -21.40, Overvalued between -5.89 and 1.87, and Strongly Overvalued above 1.87. The current Forward EV/EBITDA of -57.24 falls within the Strongly Undervalued range.

-40.69

EV/EBIT

BridgeBio Pharma Inc. (BBIO) has a current EV/EBIT of -40.69. The 5-year average EV/EBIT is -11.02. The thresholds are as follows: Strongly Undervalued below -20.85, Undervalued between -20.85 and -15.94, Fairly Valued between -6.10 and -15.94, Overvalued between -6.10 and -1.19, and Strongly Overvalued above -1.19. The current Forward EV/EBIT of -40.69 falls within the Strongly Undervalued range.

61.98

BridgeBio Pharma Inc. (BBIO) has a current PS of 61.98. The 5-year average PS is 86.72. The thresholds are as follows: Strongly Undervalued below -62.67, Undervalued between -62.67 and 12.03, Fairly Valued between 161.42 and 12.03, Overvalued between 161.42 and 236.12, and Strongly Overvalued above 236.12. The current Forward PS of 61.98 falls within the Historic Trend Line -Fairly Valued range.

-32.30

P/OCF

BridgeBio Pharma Inc. (BBIO) has a current P/OCF of -32.30. The 5-year average P/OCF is -13.07. The thresholds are as follows: Strongly Undervalued below -29.84, Undervalued between -29.84 and -21.45, Fairly Valued between -4.68 and -21.45, Overvalued between -4.68 and 3.70, and Strongly Overvalued above 3.70. The current Forward P/OCF of -32.30 falls within the Strongly Undervalued range.

-50.38

P/FCF

BridgeBio Pharma Inc. (BBIO) has a current P/FCF of -50.38. The 5-year average P/FCF is -12.51. The thresholds are as follows: Strongly Undervalued below -26.14, Undervalued between -26.14 and -19.32, Fairly Valued between -5.69 and -19.32, Overvalued between -5.69 and 1.12, and Strongly Overvalued above 1.12. The current Forward P/FCF of -50.38 falls within the Strongly Undervalued range.

BridgeBio Pharma Inc (BBIO) has a current Price-to-Book (P/B) ratio of -6.24. Compared to its 3-year average P/B ratio of -3.85 , the current P/B ratio is approximately 62.34% higher. Relative to its 5-year average P/B ratio of 3.11, the current P/B ratio is about -300.82% higher. BridgeBio Pharma Inc (BBIO) has a Forward Free Cash Flow (FCF) yield of approximately -4.85%. Compared to its 3-year average FCF yield of -12.36%, the current FCF yield is approximately -60.74% lower. Relative to its 5-year average FCF yield of -14.87% , the current FCF yield is about -67.36% lower.

-6.18

P/B

Median3y

-3.85

Median5y

3.11

-0.05

FCF Yield

Median3y

-12.36

Median5y

-14.87

Competitors Valuation Multiple

The average P/S ratio for BBIO's competitors is 42.27, providing a benchmark for relative valuation. BridgeBio Pharma Inc Corp (BBIO) exhibits a P/S ratio of 61.98, which is 46.63% above the industry average. Given its robust revenue growth of 4318.01%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Elanco Animal Health Inc

BioMarin Pharmaceutical Inc

Avidity Biosciences Inc

Summit Therapeutics Inc

18.91

13.56B

Performance Decomposition

Market capitalization of BBIO increased by 128.79% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 2.73M to 120.70M.

The secondary factor is the Margin Expansion, contributed -97.45%to the performance.

Overall, the performance of BBIO in the past 1 year is driven by Revenue Growth. Which is more sustainable.

4318.01%

2.73M → 120.70M

Revenue Growth

-97.45%

-6.01K → -153.22

Margin Expansion

-4091.77%

0.37 → -14.81

P/E Change

128.79%